Alcidion Group Limited (ASX:ALC)
Australia · Delayed Price · Currency is AUD | Market Cap | 134.30M +5.3% |
| Revenue (ttm) | 48.62M +36.4% |
| Net Income | 3.87M |
| EPS | 0.00 |
| Shares Out | 1.34B |
| PE Ratio | 35.06 |
| Forward PE | 90.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 330,169 |
| Open | 0.0990 |
| Previous Close | 0.1000 |
| Day's Range | 0.0990 - 0.1020 |
| 52-Week Range | 0.0820 - 0.1450 |
| Beta | 1.10 |
| Analysts | Buy |
| Price Target | 0.15 (+51.52%) |
| Earnings Date | Apr 29, 2026 |
About Alcidion Group
Alcidion Group Limited, together with its subsidiaries, engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom. It offers Miya Precision, a fast healthcare interoperability resource (FHIR)-events platform that integrates digital patient care services, such as a clinical decision support system, electronic patient record (EPR), and patient administration systems (PAS). The company platform also provides electronic patient flow journey boards; virtual care and remote patient mana... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ALC stock is "Buy." The 12-month stock price target is $0.15, which is an increase of 51.52% from the latest price.
News
Alcidion Signs Contract With University Hospitals Sussex For Miya Precision EPR Platform
(RTTNews) - Alcidion Group (ALC.AX) has signed a contract with University Hospitals Sussex for Miya Precision EPR platform. The platform will give clinicians real time access to patient records whilst...
Alcidion Group Earnings Call Transcript: Q3 2026
Q3 FY2026 saw strong new sales, contract expansions, and strategic wins in the U.K. and Australia, driving recurring revenue and positive cash flow. Revenue is expected to exceed AUD 50 million for the year, with significant growth anticipated in Q4 and continued geographic expansion.
Alcidion Group Earnings release: Q3 2026
Alcidion Group released its Q3 2026 earnings on April 28, 2026, summarizing the period's financial results.
Alcidion Group Earnings Call Transcript: H1 2026
Record H1 revenue and EBITDA growth were driven by recurring revenue and major contract wins, especially in the UK. Guidance for FY 2026 anticipates revenue above AUD 50 million, with continued expansion into new markets and a strong sales pipeline.
Alcidion Group Quarterly report: H1 2026
Alcidion Group has published its H1 2026 quarterly earnings report on February 25, 2026.
Alcidion Group Slides: H1 2026
Alcidion Group has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 25, 2026.
Alcidion Group Earnings release: H1 2026
Alcidion Group released its H1 2026 earnings on February 25, 2026, summarizing the period's financial results.
Alcidion Group Earnings Call Transcript: Q2 2026
Q2 FY 2026 saw strong contract wins, including a major Leidos expansion and selection as preferred provider for UHS Sussex, driving a 40% year-over-year increase in contracted revenue. Cash position remains robust, with positive outlook for FY 2026 pending further contract finalizations.
Alcidion Group Earnings release: Q2 2026
Alcidion Group released its Q2 2026 earnings on January 14, 2026, summarizing the period's financial results.
Alcidion Group Earnings Call Transcript: Q1 2026
Strongest Q1 in two years with AUD 8.2M in new sales and improved cash flow. Major contract expansions and successful deployments in the UK and Australia underpin positive FY 2026 guidance, with continued focus on international growth and digital innovation.
Alcidion Group Earnings release: Q1 2026
Alcidion Group released its Q1 2026 earnings on October 27, 2025, summarizing the period's financial results.
Alcidion Group Transcript: AGM 2025
Record FY2025 results included strong revenue growth, improved EBITDA, and a robust cash position. Strategic focus remains on expanding the Miya Precision platform, entering new markets, and addressing healthcare sector challenges, with board renewal and shareholder engagement ongoing.
Alcidion Group Slides: FY 2025
Alcidion Group has posted slides in relation to its FY 2025 quarterly earnings report, which was published on October 16, 2025.
Alcidion Group Slides: Investor Presentation
Alcidion Group has posted slides in relation to its latest quarterly earnings report, which was published on September 14, 2025.
Alcidion Group Earnings Call Transcript: H2 2025
Record FY 2025 results included 10% revenue growth to $40.8M, ARR up 31% to $28.5M, and maiden net profit after tax of $1.7M. UK revenue surpassed ANZ, and a $39M North Cumbria contract was signed. Entering FY 2026 with $34M contracted revenue and strong growth outlook.
Alcidion Group Annual report: H2 2025
Alcidion Group has published its H2 2025 annual report on August 27, 2025.
Alcidion Group Slides: H2 2025
Alcidion Group has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 27, 2025.
Alcidion Group Earnings release: H2 2025
Alcidion Group released its H2 2025 earnings on August 27, 2025, summarizing the period's financial results.
Alcidion Group Earnings Call Transcript: Q4 2025
Q4 delivered record financial results, with strong new sales, cash flow, and major contract expansions. FY 2025 EBITDA is set to exceed AUD 4.5 million, and momentum continues in both core and new markets, supported by robust demand for digital health solutions.
Alcidion Group Earnings release: Q4 2025
Alcidion Group released its Q4 2025 earnings on July 23, 2025, summarizing the period's financial results.